InGeneron, Inc. news
InGeneron, Inc., a clinical stage biotechnology company, announced the publication of a succinct scientific review of regenerative cell therapy, commonly called “stem cell therapy”, to treat orthopedic indications. This newly released paper, titled “Perspective: Why and how to use the body’s own stem cells for regeneration in musculoskeletal disorders: a primer“, was published in the Journal of Ort
InGeneron, Inc., a clinical stage biotechnology company, today announced that the American Medical Association’s (AMA) Current Procedural Terminology (CPT®) Editorial Panel has issued two new Category III CPT® codes for the company’s autologous, adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tears. The newly published codes (0717T, 0718T) will become effective on July 1, 2022 and mark an important step for
InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, announced the publication of the first comprehensive analysis providing significant support for the existence of naturally pluripotent stem cells in all organs. Pluripotent stem cells have the ability to become any cell type of the adult body. The newly-released publication, entitled “Perspective: Why and How Ubiquitously Distributed, Vascular-Associated
InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, today announced the publication of the first-in-human comprehensive immunohistochemical evaluation of adult tendon repair following the local injection of fresh, uncultured, unmodified, autologous, adipose derived regenerative cells (UA-ADRCs). This newly-released research paper, titled “First Immunohistochemical Evidence of Human Tend
InGeneron, Inc., a regenerative medicine and cell therapy company, today announced the publication of promising results in developing a novel treatment for chronic ischemic heart failure using its regenerative cell therapy platform.
A newly-released research paper published in the World Journal of Stem Cells provides missing pieces of evidence for a fundamental change in the treatment of chronic ischemic heart failure, showing efficacy and safety of a novel stem cell treatment in card